spacer
spacer

PDBsum entry 4ztf

Go to PDB code: 
protein dna_rna ligands metals Protein-protein interface(s) links
Transferase/DNA/inhibitor PDB id
4ztf

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
368 a.a.
184 a.a.
DNA/RNA
Ligands
GOL ×4
X2P
SO4 ×3
Metals
_MG ×3
_ZN
Waters ×159
PDB id:
4ztf
Name: Transferase/DNA/inhibitor
Title: Crystal structure of the prototype foamy virus intasome with a 2- pyridinone aminal inhibitor
Structure: Integrase. Chain: a, b. Synonym: pr125pol. Engineered: yes. 19 nucleotide preprocessed pfv donor DNA (non-transferred strand). Chain: c. Engineered: yes. 17 nucleotide preprocessed pfv donor DNA (transferred
Source: Human spumaretrovirus. Sfvcpz(hu). Organism_taxid: 11963. Gene: pol. Expressed in: escherichia coli. Expression_system_taxid: 562. Synthetic: yes. Organism_taxid: 11963
Resolution:
2.70Å     R-factor:   0.192     R-free:   0.215
Authors: D.J.Klein,S.Patel
Key ref: I.T.Raheem et al. (2015). Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors. J Med Chem, 58, 8154-8165. PubMed id: 26397965 DOI: 10.1021/acs.jmedchem.5b01037
Date:
14-May-15     Release date:   07-Oct-15    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
P14350  (POL_FOAMV) -  Pro-Pol polyprotein from Human spumaretrovirus
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1143 a.a.
368 a.a.*
Protein chain
P14350  (POL_FOAMV) -  Pro-Pol polyprotein from Human spumaretrovirus
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1143 a.a.
184 a.a.*
Key:    Secondary structure  CATH domain
* PDB and UniProt seqs differ at 4 residue positions (black crosses)

DNA/RNA chains
  A-T-T-G-T-C-A-T-G-G-A-A-T-T-T-C-G-C-A 19 bases
  T-G-C-G-A-A-A-T-T-C-C-A-T-G-A-C-A 17 bases

 Enzyme reactions 
   Enzyme class 2: Chains A, B: E.C.2.7.7.-  - ?????
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 3: Chains A, B: E.C.2.7.7.49  - RNA-directed Dna polymerase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
DNA(n)
+ 2'-deoxyribonucleoside 5'-triphosphate
= DNA(n+1)
+ diphosphate
   Enzyme class 4: Chains A, B: E.C.2.7.7.7  - DNA-directed Dna polymerase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
DNA(n)
+ 2'-deoxyribonucleoside 5'-triphosphate
= DNA(n+1)
+ diphosphate
   Enzyme class 5: Chains A, B: E.C.3.1.-.-
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 6: Chains A, B: E.C.3.1.26.4  - ribonuclease H.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Endonucleolytic cleavage to 5'-phosphomonoester.
   Enzyme class 7: Chains A, B: E.C.3.4.23.-  - ?????
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
Note, where more than one E.C. class is given (as above), each may correspond to a different protein domain or, in the case of polyprotein precursors, to a different mature protein.
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    reference    
 
 
DOI no: 10.1021/acs.jmedchem.5b01037 J Med Chem 58:8154-8165 (2015)
PubMed id: 26397965  
 
 
Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.
I.T.Raheem, A.M.Walji, D.Klein, J.M.Sanders, D.A.Powell, P.Abeywickrema, G.Barbe, A.Bennet, K.Childers, M.Christensen, S.D.Clas, D.Dubost, M.Embrey, J.Grobler, M.J.Hafey, T.J.Hartingh, D.J.Hazuda, J.T.Kuethe, J.McCabe Dunn, M.D.Miller, K.P.Moore, A.Nolting, N.Pajkovic, S.Patel, Z.Peng, V.Rada, P.Rearden, J.D.Schreier, J.Sisko, T.G.Steele, J.F.Truchon, J.Wai, M.Xu, P.J.Coleman.
 
  ABSTRACT  
 
The search for new molecular constructs that resemble the critical two-metal binding pharmacophore required for HIV integrase strand transfer inhibition represents a vibrant area of research within drug discovery. Here we present the discovery of a new class of HIV integrase strand transfer inhibitors based on the 2-pyridinone core of MK-0536. These efforts led to the identification of two lead compounds with excellent antiviral activity and preclinical pharmacokinetic profiles to support a once-daily human dose prediction. Dose escalating PK studies in dog revealed significant issues with limited oral absorption and required an innovative prodrug strategy to enhance the high-dose plasma exposures of the parent molecules.
 

 

spacer

spacer